2022
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
Johnston K, Powell L, Popoff E, Harris L, Croop R, Coric V, L’Italien G. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. The Clinical Journal Of Pain 2022, 38: 680-685. PMID: 36125279, PMCID: PMC9555761, DOI: 10.1097/ajp.0000000000001072.Peer-Reviewed Original ResearchConceptsBenefit-risk profilePain freedomPain reliefAcute treatmentRisk differenceMost bothersome symptomsSustained pain reliefFixed-effect Bayesian NMALasmiditan 200Lasmiditan 50Lowest NNTPooled placeboBothersome symptomsBayesian NMAClinical trialsSafety outcomesLasmiditanNauseaDizzinessTrialsPlaceboMigraineNNTTreatmentHours
2020
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin
2019
Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States
Elion RA, Kabiri M, Mayer KH, Wohl DA, Cohen J, Beaubrun AC, Altice FL. Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. International Journal Of Environmental Research And Public Health 2019, 16: 1592. PMID: 31067679, PMCID: PMC6539923, DOI: 10.3390/ijerph16091592.Peer-Reviewed Original ResearchConceptsYoung Latino MSMYoung Black MSMPre-exposure prophylaxisBlack MSMLatino MSMPrEP useHIV Incidence Risk IndexHuman immunodeficiency virus (HIV) transmissionUse of PrEPNon-PrEP usersLowest NNTHIV infectionNNT valuesHIV prevalenceHIV epidemicHIV preventionMSM populationSubsequent infectionInfection reductionMSMPrevalenceIncidenceVirus transmissionPrEPProphylaxis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply